If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

PSE - Awards Finalist

5 Jun 2007 11:03

Imperial Innovations Group plc05 June 2007 5 June 2007 Imperial Innovations Group plc ("Imperial Innovations") PSE Finalist for MacRobert Award Imperial Innovations Group plc (AIM: IVO), the technology commercialisation andinvestment company, announces that an Imperial Innovations spin-out company,Process Systems Enterprise (PSE), was today revealed to be one of the fourfinalists for the Royal Academy of Engineering's MacRobert Award. The award, theUK's most prestigious for engineering, recognises the successful development ofinnovative ideas in engineering. The winning company is honoured with a goldmedal and the winning team members receive a prize of £50,000. Process Systems Enterprise was selected for its innovative gPROMS(R) advancedprocess modelling software. gPROMS helps process industry companies to maximiseproduct quality, minimise production cost and control environmental impactthrough the use of high-accuracy predictive mathematical models of theirprocesses. It also enables them to innovate much faster, design more efficientprocesses, manage risk closely and integrate R&D and engineering disciplines. gPROMS has successfully entered the worldwide market, with 75% of PSE's revenuescoming from exports. The company's client base includes more than 60 of theworld's leading process industry companies, about 75% of which are Fortune 500organisations. gPROMS is also being used for teaching and research by more than200 universities worldwide. The company was formed in 1997 by Imperial Innovations and is based ontechnology arising from the research of Professor Costas Pantelides andcolleagues from the Centre for Process Systems Engineering at Imperial CollegeLondon. Prof. Costas Pantelides, MD of PSE, says "The process industry is going througha period of significant opportunities and challenges: unprecedented demand forproducts, increasing customer expectations of product performance, decreasingavailability of primary raw materials, and global concerns relating to energyconsumption, safety and environmental impact. We bring the means to make sounddecisions while minimising the risk inherent in innovation". Susan Searle, CEO of Imperial Innovations said, "Imperial Innovations isdelighted that PSE is being considered for the MacRobert awards. We recognisethe tremendous progress and future potential of PSE, and are working with thecompany closely to develop new geographical markets and sectors for its growth.In particular, we see that PSE has major potential in the environment sectorwhere companies are designing new product manufacturing methods with lowercarbon footprints and large metropolitan areas are developing moreenvironmentally sustainable urban systems. We are helping PSE find new channelpartners to accelerate its growth and realise its full potential." -Ends- For more information contact: Imperial InnovationsSusan Searle, Chief Executive Officer +44 (0)20 7594 6591Lucy Ahfong, Marketing Communications Executive +44 (0)20 7594 6644 M:CommunicationsHarriet Totty / Eleanor Williamson +44 (0)20 7153 1539 JP Morgan Cazenove +44 (0)20 7588 2828Steve Baldwin Notes to Editors About Imperial InnovationsImperial Innovations is one of the UK's leading technology transfer andcommercialisation companies. The company was founded in 1986 and its ordinaryshares admitted to trading on the AIM Market of London Stock Exchange plc inJuly 2006, raising £26 million. The company's integrated approach encompassesthe identification of ideas, protection of intellectual property, developmentand licensing of technology and formation, incubation and investment intechnology businesses. A wide range of technologies are commercialised withinthe areas of healthcare, energy, environment and emerging technology trends. Based at Imperial College London, the company has established equity holdings in70 technology businesses and has completed 116 commercial agreements. ImperialInnovations also commercialises technologies originating from outside ImperialCollege through incubation contracts with the Carbon Trust and WRAP and hasrelationships with a number of multinational corporations including BAE Systems. Imperial Innovations has invested in a range of spin-out companies, includingThe Acrobot Company Limited, BioCeramic Therapeutics Limited, Cardiak Limited,Circassia Holdings Limited, deltaDOT Limited, Equinox Pharma Limited, FutureWaves PTE Limited, HeliSwirl Technologies Limited, InforSense Limited, IXICOLimited, Lontra Limited, Midaz Lasers Limited, NanoBioDesign Limited, NexeonLimited, NovaThera Limited, Thiakis Limited and Veryan Medical Limited. Imperial Innovations currently holds shares in four technology businesses nowlisted on AIM including the fuel cell company, Ceres Power plc. www.imperialinnovations.co.uk About Process Systems Enterprise Ltd PSE (www.psenterprise.com) is one of the world's foremost providers of AdvancedProcess Modelling software and Model-Based Innovation services to the processmanufacturing industries. These apply high-accuracy mathematical models ofprocess equipment and phenomena to provide high-quality information for decisionsupport in process innovation, design and operation. Use of PSE's technology and services results in faster innovation, improveddesigns of processes and products, enhancement of existing operations and moreeffective R&D and experimental programmes. Results are achieved with relativelylow investment compared to alternative approaches - where these exist - withrapid return on investment and transfer of modelling know-how to industry. PSE's global customer base of process manufacturing companies and theirtechnology suppliers is served by offices in the UK, USA, Germany and Japan, andagencies in China, India and Korea. About gPROMS gPROMS(R) is the world's leading Advanced Process Modelling (APM) environment.It is used to provide high-quality information for decision support ininnovation, design and operation across all sectors of the process industries,with particular focus on modelling of complex operations such as reaction,crystallisation and polymerisation. Companies apply gPROMS to reduce time-to-market for new processes or products,improve designs, enhance production, reduce capital and operating expenditureand comply more effectively with safety, health and environmental requirements. gPROMS is applied across the 'process lifecycle', from laboratoryexperimentation, through process and detailed design, to online operation, andis central to the emerging technology of Model-Based Innovation. PSE iscommitted to maintaining gPROMS at the leading edge of modelling technology. http://www.psenterprise.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
5th Sep 20162:40 pmRNSHolding(s) in Company
24th Aug 20167:01 amRNSCell Medica and UCL collaboration
12th Jul 20167:02 amRNSCell Medica acquires Delenex Therapeutics
6th Jul 20167:00 amRNSEconic raises £5m to develop novel catalyst tech
30th Jun 201612:11 pmRNSPsiOxus and Bristol-Myers Squibb collaboration
28th Jun 20167:00 amRNSStorm Therapeutics raises £12m
21st Jun 20164:35 pmRNSPrice Monitoring Extension
21st Jun 20167:00 amRNSDirector's share purchase
20th Jun 20167:03 amRNSCircassia cat allergy Phase III study
17th Jun 20167:00 amRNSCell Medica and Baylor College of Medicine partner
16th Jun 201610:44 amRNSReplacement Holding(s) in Company
14th Jun 20163:20 pmRNSEdison issues outlook on Imperial Innovations)
14th Jun 20169:00 amRNSHolding(s) in Company
13th Jun 20167:00 amRNSAllotment of Deferred Placing Shares
31st May 20167:00 amRNSFeaturespace closes £6.2 million funding round
26th May 20167:00 amRNS£3 million funding round for Inflowmatix
11th May 201612:32 pmRNSDavid Newlands appointed Chairman
4th May 20164:35 pmRNSPrice Monitoring Extension
4th May 201611:08 amRNSNexeon raises £30m, plans development lab in Asia
4th May 20167:00 amRNSAnalyst and Investor day
29th Apr 20164:35 pmRNSPrice Monitoring Extension
29th Apr 201612:42 pmRNSSale of Innovations portfolio Stanmore Implants
7th Apr 20167:00 amRNSHalf Yearly Report
21st Mar 20167:00 amRNSDr Martin Knight to step down from the board
18th Mar 201612:40 pmRNSNotice of Results
17th Mar 20167:00 amRNSTopiVert reports successful Phase I clinical study
26th Feb 20168:39 amRNSHolding(s) in Company
25th Feb 20163:59 pmRNSHolding(s) in Company
25th Feb 20163:50 pmRNSHolding(s) in Company
25th Feb 20168:53 amRNSHolding(s) in Company
22nd Feb 20165:01 pmRNSAdmission of shares to trading on AIM
22nd Feb 201612:29 pmRNSResult of General Meeting
22nd Feb 20167:00 amRNS£13.5m funding round in Precision Ocular
11th Feb 20162:51 pmRNSHolding(s) in Company
8th Feb 20167:00 amRNSInnovations leads £5m Series A round in Aqdot
4th Feb 20166:08 pmRNSResult of Placing
4th Feb 20167:00 amRNSPlacing to raise £100 million
2nd Feb 20167:00 amRNSMISSION Therapeutics raises £60 million
26th Jan 20167:00 amRNSInivata completes £31.5m Series A funding round
25th Jan 20167:00 amRNSInnovations joins Apollo consortium
18th Jan 20167:00 amRNSInnovations invests £25m in new £50m UCL Tech Fund
2nd Dec 20157:00 amRNSKesios Therapeutics raises £19 million
19th Nov 20151:51 pmRNSResult of AGM
4th Nov 20151:40 pmRNSGrant of share options
28th Oct 20157:00 amRNSPosting of Annual Report and Notice of AGM
22nd Oct 20157:00 amRNSLeads £1.5m seed funding into AI pioneer, Telectic
14th Oct 20157:00 amRNSFinal Results
22nd Sep 20154:10 pmRNSNotice of Results
12th Aug 20157:00 amRNSIssue of Equity
4th Aug 20157:01 amRNS£2.5m funding round in Oxford Biotrans

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.